美容护理行业跟踪报告：25Q4美护基金配置比例环比下滑，个护、化妆品处于低配区间

Investment Rating - The investment rating for the beauty and personal care industry is "outperforming the market" [4][22]. Core Insights - The fund allocation ratio for the beauty and personal care industry decreased to 0.14% in Q4 2025, down 0.06 percentage points from Q3 2025, indicating a continued low allocation status [1][3][9]. - The total market capitalization of the beauty and personal care industry reached 255.096 billion yuan in Q4 2025, reflecting a 10.43% decrease from Q3 2025 [1][9]. - The medical beauty sector remains in an over-allocated position, while personal care and cosmetics are in a low allocation zone [2][11]. Summary by Sections Industry Overview - In Q4 2025, the fund allocation ratio for personal care products was 0.03%, down 0.01 percentage points from Q3 2025, with an over-allocation ratio of -0.04% [2][13]. - The cosmetics sector saw a fund allocation ratio of 0.02% in Q4 2025, down 0.02 percentage points from Q3 2025, with an over-allocation ratio of -0.1% [2][13]. - The medical beauty sector's fund allocation ratio was 0.09% in Q4 2025, down 0.03 percentage points from Q3 2025, with an over-allocation ratio of 0.02% [2][13]. Individual Stocks - The top three stocks in the beauty and personal care sector by fund allocation in Q4 2025 were Jinbo Biological, Aimeike, and Baiya Shares, with a total heavy holding ratio of 0.05%, down 0.02 percentage points from Q3 2025 [2][15][19]. - Jinbo Biological had a heavy holding ratio of 0.0163%, Aimeike at 0.0156%, and Baiya Shares at 0.0040% in Q4 2025, all showing a decline compared to Q3 2025 [15][19]. Investment Recommendations - In the context of stabilizing the economy and expanding domestic demand, it is recommended to focus on: 1. Cosmetics and medical beauty: There is significant demand potential in the medium to long term, supported by regulatory policies favoring compliant companies [3][20]. 2. Personal care products: The growing emphasis on health and wellness among consumers suggests opportunities for leading companies with strong R&D capabilities [3][20].